Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
0 hedge funds and large institutions have $0 invested in Alexion Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $2.16M → $0 (-$2.16M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KRS
Kentucky Retirement Systems
Frankfort,
Kentucky
|
-$2.15M |
| 2 |
ACM
Accent Capital Management
Centerville,
Ohio
|
-$6.82K |
ALXN Hedge Fund Activity: Q2 2026 in Review
0 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2026, worth a combined $0 — down 100% from $2.16M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ALXN and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Kentucky Retirement Systems, exiting entirely with an estimated $2.15M sold.
- 0 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2026, down from 2 in Q1 2026.
- Funds reported $0 of Alexion Pharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
- 0 funds opened new Alexion Pharmaceuticals positions in Q2 2026 and 2 closed out, a net change of -2 holders.
- The largest Alexion Pharmaceuticals seller in Q2 2026 was Kentucky Retirement Systems, an estimated $2.15M sold.
Based on aggregated 13F filings for Q2 2026.